Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

47.00 -1.36 (-2.81%)
Streaming Delayed Price Updated: 3:46 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 690,664
Open 47.99
Bid (Size) 47.00 (1)
Ask (Size) 47.06 (6)
Prev. Close 48.36
Today's Range 46.57 - 48.68
52wk Range 24.22 - 60.60
Shares Outstanding 59,598,018
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
Via ACCESS Newswire
D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
Mid-cap stocks were top performers last week. D-Wave, Protagonist, Veren, IonQ, Rigetti, Semtech, Orla Mining, and Hesai all saw significant gains. 
Via Benzinga

Performance

YTD
+20.6%
+20.6%
1 Month
+22.1%
+22.1%
3 Month
+22.0%
+22.0%
6 Month
+4.4%
+4.4%
1 Year
+66.2%
+66.2%

More News

Read More
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Keep an eye on the top gainers and losers in Monday's session.
Via Chartmill
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Via ACCESS Newswire
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
Via ACCESSWIRE
Monday's session: top gainers and losers
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
Top movers in Monday's pre-market session
Via Chartmill
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
Via Benzinga
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
Via Investor's Business Daily
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
Via ACCESS Newswire
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
Via ACCESS Newswire
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Via Benzinga
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) is a candidate for growth investors. Here's why.
Via Chartmill
Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
Via ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Awards
Via ACCESSWIRE
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Via ACCESSWIRE
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
Via ACCESSWIRE
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday
Via Benzinga
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
Via ACCESSWIRE
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Via ACCESSWIRE
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
Via ACCESSWIRE

Frequently Asked Questions

Is Protagonist Therapeutics, Inc. - Common Stock publicly traded?
Yes, Protagonist Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Protagonist Therapeutics, Inc. - Common Stock trade on?
Protagonist Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Protagonist Therapeutics, Inc. - Common Stock?
The ticker symbol for Protagonist Therapeutics, Inc. - Common Stock is PTGX on the Nasdaq Stock Market
What is the current price of Protagonist Therapeutics, Inc. - Common Stock?
The current price of Protagonist Therapeutics, Inc. - Common Stock is 47.00
When was Protagonist Therapeutics, Inc. - Common Stock last traded?
The last trade of Protagonist Therapeutics, Inc. - Common Stock was at 04/01/25 03:46 PM ET
What is the market capitalization of Protagonist Therapeutics, Inc. - Common Stock?
The market capitalization of Protagonist Therapeutics, Inc. - Common Stock is 2.80B
How many shares of Protagonist Therapeutics, Inc. - Common Stock are outstanding?
Protagonist Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.